Eun Yang
Stock Analyst at Jefferies
(0.62)
# 3,834
Out of 4,761 analysts
46
Total ratings
37.04%
Success rate
-25.94%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $361.10 | +19.63% | 8 | Sep 23, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: Hold | $65 → $2 | $2.37 | -15.61% | 3 | Jun 17, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $1.61 | +396.89% | 2 | May 14, 2024 | |
| ATXS Astria Therapeutics | Maintains: Buy | $22 → $27 | $6.81 | +296.48% | 2 | Mar 25, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $7 → $1.5 | $0.75 | +98.94% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $36.85 | -10.45% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $3.46 | +709.25% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $21.80 | +23.85% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $3.18 | +120.13% | 1 | Feb 10, 2023 | |
| CVAC CureVac | Upgrades: Buy | n/a | $3.30 | - | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $2.97 | +743.17% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $75 | $1.09 | +6,780.73% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $84 | $92.25 | -8.94% | 3 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.28 | +1,853.13% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $7.28 | - | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $16.63 | +110.46% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $303.01 | -27.40% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $38 → $31 | $13.17 | +135.38% | 5 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $140.64 | +120.42% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $109.95 | -27.24% | 3 | Jul 11, 2017 |
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $361.10
Upside: +19.63%
Aerovate Therapeutics
Jun 17, 2024
Downgrades: Hold
Price Target: $65 → $2
Current: $2.37
Upside: -15.61%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $1.61
Upside: +396.89%
Astria Therapeutics
Mar 25, 2024
Maintains: Buy
Price Target: $22 → $27
Current: $6.81
Upside: +296.48%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $7 → $1.5
Current: $0.75
Upside: +98.94%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $36.85
Upside: -10.45%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $3.46
Upside: +709.25%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $21.80
Upside: +23.85%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $3.18
Upside: +120.13%
CureVac
Jan 9, 2023
Upgrades: Buy
Price Target: n/a
Current: $3.30
Upside: -
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $2.97
Upside: +743.17%
Sep 22, 2022
Maintains: Buy
Price Target: $525 → $75
Current: $1.09
Upside: +6,780.73%
Aug 22, 2022
Maintains: Buy
Price Target: $78 → $84
Current: $92.25
Upside: -8.94%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $1.28
Upside: +1,853.13%
Jul 12, 2021
Initiates: Buy
Price Target: n/a
Current: $7.28
Upside: -
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $16.63
Upside: +110.46%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $303.01
Upside: -27.40%
Nov 3, 2017
Maintains: Hold
Price Target: $38 → $31
Current: $13.17
Upside: +135.38%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $140.64
Upside: +120.42%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $109.95
Upside: -27.24%